Abstracts tagged "antiphospholipid antibodies and thrombosis"

Abstract Number: 854 • 2018 ACR/ARHP Annual Meeting
First and Recurrent Thrombosis Risk after 1897 Patient-Years of Follow-up: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Ecem Sevim¹, Ozan Unlu², Danieli Andrade³, Alessandra Banzato⁴, Maria Tektonidou⁵, Amaia Ugarte⁶, Maria Gerosa⁷, Hannah Cohen⁸, David Branch⁹, Guilherme Ramires de Jesus¹⁰, Angela Tincani¹¹, Paul R. Fortin¹², Michelle Petri¹³, Ignasi Rodriguez¹⁴, Jason S Knight¹⁵, Tatsuya Atsumi¹⁶, Rohan Willis¹⁷, Robert Roubey¹⁸ and Doruk Erkan¹⁹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, USA., New York, NY, ³Rheumatology, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy, ⁵Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ⁶Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, ⁷Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁸Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ⁹Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁰Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹¹University and Spedali Civili of Brescia, Brescia, Italy, ¹²Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴Rheumatology, Hospital Clinica, Barcelona, Spain, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁷301 University Blvd, Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, USA, Galveston, TX, ¹⁸Rheumatology, Allergy, and Immunology, Department of Medicine and Thurston Arthritis Research Center, Division of Rheumatology, Allergy and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹⁹Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
Abstract Number: 1065 • 2016 ACR/ARHP Annual Meeting
A Practical Application of Antiphospholipid Antibodies Profiles in the Diagnosis and Managements of Antiphospholipid Syndrome: The Modified Antiphospholipid Score
Kenji Oku¹, Olga Amengual², Kazumasa Ohmura¹, Masaru Kato³, Toshiyuki Bohgaki¹, Tetsuya Horita¹, Shinsuke Yasuda¹, Eriko Morishita⁴, Masahiro Ieko⁵ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Hokkaido University,Medicine II, Sapporo, Japan, ³Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁴College of Medical, Pharmaceutical and Health Science Kanazawa University, Kanazawa, Japan, ⁵Health Science University of Hokkaido, Toubetsu, Japan
Background/Purpose: The clinical scoring systems to quantify the probability for the diagnosis of antiphospholipid syndrome (APS) or future thrombosis, have been proposed as to reflect…
Abstract Number: 1069 • 2016 ACR/ARHP Annual Meeting
The Predictive Value of Acl and Anti-β2GPI in Patients with Acute Deep Vein Thrombosis
Katja Perdan-Pirkmajer¹, Anja Boc², Saša Čučnik¹, Alenka Mavri³, Polona Žigon¹, Monika Štalc⁴, Nina Vene⁵ and Ales Ambrozic⁶, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Medicine, Institute of Anatomy, University of Ljubljana, Ljubljana, Slovenia, ³Deparment of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁴Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁵Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁶Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
Background/Purpose: Acute deep vein thrombosis (DVT) is generally treated with anticoagulants for 3 to 6 months. Antiphospholipid syndrome (APS) is an important cause of DVT.…
Abstract Number: 2101 • 2016 ACR/ARHP Annual Meeting
the Association Between ABO Blood Types and Venous Thromboembolism in Individuals with a Positive Antiphospholipid Antibody Profile Is Varied By Sex
Michael Shusterman¹, Eugeniya Golub¹, Wenzhu Mowrey² and Anna R. Broder³, ¹Medicine, Montefiore Health Systems, Bronx, NY, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Medicine/Rheumatology, Division of Rheumatology, Albert Einstein College of Med, Bronx, NY
Background/Purpose: Venous thrombotic events (VTE) are the most common complications in patients with persistently positive aPL antibodies (aPL+)1 . The pathogenesis of VTE is multifactorial,…
Abstract Number: 2189 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository (“Registry”) Prospective Follow-up Analysis: One-Year First and Recurrent Thrombosis Risk
Doruk Erkan¹, Stephane Zuily², Alessandra Banzato³, Karel De Ceulaer⁴, Hannah Cohen⁵, Maria Tektonidou⁶, Danieli Andrade⁷ and , on Behalf of APS ACTION .⁸, ¹Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, ²Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Vascular Medicine Unit, Vandoeuvre-Les-Nancy, France, ³Department of Cardiac Thoracic and Vascular Sciences, (2) Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua Italy, Padua, Italy, ⁴Internal Medicine, University of the West Indies, Kgn 7, Jamaica, ⁵Hematology., University College London, LOndon, United Kingdom, ⁶First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ⁷Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, ⁸., New York, NY
Background/Purpose: APS ACTION “Registry” was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].